FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(b) of the Investment Company Act of 1940

			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				X	Director	10% Owner			
(Last) 62 OSBORNE RO	(First) (Middle) BORNE ROAD		3. Date of Earliest Transaction (Month/Day/Year) 02/10/2017		Officer (give title below)	Other (specify below)			
(Street) GARDEN CITY	NY	11530	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	idual or Joint/Group Filing (Che Form filed by One Reporting Form filed by More than On	g Person			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (li 8)		4. Securities Ac Disposed Of (D			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	02/10/2017		Α		10,866	Α	\$3	60,866	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (II 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option	\$3.7							(1)	02/19/2026	Common Stock	15,000		15,000	D	
Warrant	\$5							03/01/2016	03/01/2021	Common Stock	37,500		37,500	D	
Warrant	\$5							05/18/2016	05/18/2021	Common Stock	12,500		12,500	D	
Stock Option	\$3.73							(2)	06/10/2026	Common Stock	29,000		29,000	D	
Warrant	\$4							08/05/2016	08/05/2021	Common Stock	8,000		8,000	D	
Warrant	\$4	02/10/2017		Α		10,866		02/10/2017	02/10/2022	Common Stock	10,866	\$0 ⁽³⁾	10,866	D	

Explanation of Responses:

1. The option vests to the extent of 5,000 shares on each of February 19, 2017, 2018 and 2019.

2. The option vests to the extent of 9,667 shares on each of June 10, 2016 and June 10, 2017, and 9,666 shares on June 10, 2018.

3. The warrant was issued in consideration of a concurrent acquisition by the Reporting Person from the Issuer of 10,866 shares.

Robert B. Catell

** Signature of Reporting Person

02/13/2017 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.